Diffuse Large B-cell Lymphoma Therapeutics Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH1271 | Last Updated On: Oct 25 2022 | Available Formats

>Diffuse Large B-cell Lymphoma Therapeutics Market Expected to reach at a high CAGR of 7.50% by 2029:

Diffuse Large B-cell Lymphoma Therapeutics Market is segmented By Drug Type (Chemotherapy Drugs, Targeted Drugs (Rituximab, Polutuzumab vedotin-piiq, Pembrolizumab, Tisagenlecleucel, Ibrutinib, Others)), By End User (Hospitals, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Diffuse Large B-cell Lymphoma Therapeutics Market size was valued at USD 4,107.50 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 7.50% over the forecast period 2022 to 2029. 

Diffuse Large B-cell Lymphoma Therapeutics Market Statistics

Metrics

Details

Market CAGR

7.50%

Segments Covered

By Drug Type, By Route of Administration, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Download free sample click here

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.

Market Dynamics

The global diffuse large b-cell lymphoma therapeutics market growth is driven by the increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma), increasing preference for targeted therapies and technological advancement coupled with advanced drug therapeutics.

Increasing preference for targeted therapies is expected to drive the growth in the forecast period

Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits the Bruton's tyrosine kinase pathway. Mantle cell lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma, as well as chronic lymphocytic leukaemia and Waldenstrom macroglobulinemia, are among the B-cell lymphomas for which it has been approved.

Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.

High cost of treatment is likely to hamper the market growth

The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment. The cost to treat diffuse large B-cell lymphoma (RR DLBCL) can be high—and that’s only taking into account first- and second-line treatments that can cost as much as $200,000. A study presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting estimated the lifetime direct medical costs of third-line and subsequent treatment costs for this disease. The authors calculated the cost of third-line therapies by adding the Average Sales Price of therapies, plus the direct costs to providers in 2017. Some of the other costs considered were adverse events, treatment administration and monitoring, disease management, and future healthcare costs

They discovered that lifetime costs can vary from $600,000 to $750,000, with the costs of adverse events related to third-line treatment representing 30% of the total cost. Treatment acquisition (28%) and subsequent therapy (21%) are the other costs considered included. The lifetime cost of treating RR DLBCL can approach and surpass $1 million after including the costs of first- and second-line therapies.

COVID-19 Impact Analysis

The COVID-19 pandemic continues to endanger global health and hinder the world economy; It has been widely observed that patients with existing diffuse large b-cell lymphoma experience higher complications due to COVID-19.

The degree to which ongoing chemotherapy impacts the outcome of patients with COVID-19 remains controversial, but at least one large study shows that individuals with diffuse large b-cell lymphoma undergoing treatment when diagnosed with COVID-19 are at high risk of severe complications.  There are also data suggesting that patients with lymphoma have an increased susceptibility to infection with SARS-CoV-2. According to one report, the more intense the therapy, the greater the impact on clinical outcomes in patients who contract COVID-19. The high morbidity and mortality rates reported in patients with hematologic malignancies underscore the vulnerability of this patient population.

Most centers are screening patients beginning therapy in the out-patient clinic or even monthly on an on-going basis, or on admission to the hospital for treatment. Practices differ depending on the prevalence of COVID-19 and the availability of screening. The decision on when and how to treat in the face of a positive result must be individualized. Patients with diffuse large b-cell lymphoma who are actively undergoing treatment with an anti-CD20 antibody have an impaired response to the BNT162b2 mRNA (by Pfizer-BioNTech) COVID-19 vaccine, according to research published in Blood Advances. Patients who had any exposure to anti-CD20 therapy were less likely to have a response to the COVID-19 vaccine. Patients with an absolute lymphocyte count were also less likely to respond to the vaccine. This will create problem for patients who are presently taking therapies.

Segment Analysis

The immuno and targeted drugs segment is expected to hold the largest share in this market segment

Targeted therapeutics is a type of cancer treatment that uses drugs to precisely 'target' cancer cells without affecting normal cells. Although targeted therapy is an effective treatment, many individuals prefer to use it in combination with other therapies such as traditional or standard chemotherapy, surgery, or radiation therapy. Developments in research for DNA changes and proteins that drive cancer are proving effective to design promising treatments that target such proteins. For different types of cancers come different types of drugs that individually target distinct cancer. However, tumors are tested to check the target, and provide therapy if the drugs are available. As traditional chemotherapy can damage normal cells while killing cancer cells, the targeted therapeutics segment is expected to witness growth during the forecast period. Targeted cancer therapies market is growing due to the increasing incidences of diffuse large b-cell lymphoma (DLBCL). For instance, as per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

Robust R&D studies are underway for the development of new drugs and therapies for DLBCLs. Several products of different companies are in different phases of clinical trials and will be available in the market during the forecast period. For instance, Roche, Glofitamab (Anti-CD20 CD3 TCB, RG6026) is a T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin’s lymphoma is under Phase 1 clinical trials is expected to complete by 2022.

Geographical Analysis

North America region holds the largest market share of global diffuse large b-cell lymphoma therapeutics market

North America dominates the market owing to the factor such as increasing prevalence of diffuse large b-cell lymphoma (DLBCL) cases and rising healthcare awareness among the peoples of the region. As per the lymphoma organization, diffuse large b-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year. The estimates are expected to increase due to the rising trend in the Non-Hodgkin Lymphoma (NHL) incidence as well as DLBCL incidence in the region, combined with underlying demographic changes. It is a mature B-cell neoplasm emanating from the germinal center & post germinal center B-cells.

Furthermore, increasing focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, in order to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma which is anticipated to drive the market growth in the region. For instance, the FDA recently authorized Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).

Competitive Landscape

The global diffuse large b-cell lymphoma therapeutics market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche Ltd, Novartis AG, Celltrion, Karyopharm Therapeutics, Kite Pharma, MorphoSys AG, AbbVie, CTI BioPharma, Seagen Inc., TG Therapeutics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the wound care management devices globally. For instance, On February 19, 2019, The FDA granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) (BR) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Global Diffuse Large B-cell Lymphoma Therapeutics Market – Key Companies to Watch

F. Hoffmann-La Roche Ltd

Company Overview: Roche was founded in 1896 in Basel, Switzerland. It creates innovative medicines and diagnostic tests that help millions of patients globally. Roche was one of the first companies to bring targeted treatments to patients. With combined strength in pharmaceuticals and diagnostics, they are better equipped than any other company to drive personalized healthcare further. Two-thirds of their research and development projects are being developed with companion diagnostics. Genentech become a member of the Roche Group in March of 2009. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Product Portfolio: The company portfolio includes Rituxan (rituximab)/MabThera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia.

Key Developments: In June 2019, the U.S FDA approved Roche’s Polivy in combination with bendamustine plus Rituxan (rituximab) (BR) for people with previously treated aggressive lymphoma i.e., diffuse large B-cell lymphoma (DLBCL).

The global diffuse large b-cell lymphoma therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages. 

Frequently Asked Questions

What is the Projected CAGR value of the Diffuse Large B-cell Lymphoma Therapeutics Market?

Diffuse Large B-cell Lymphoma Therapeutics Market is expected to grow at a CAGR of 7.5% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Diffuse Large B-cell Lymphoma Therapeutics Market during 2022-2029

Which is the fastest growing region in the Diffuse Large B-cell Lymphoma Therapeutics Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

T-cell-lymphoma Market

Hodgkin’s Lymphoma Market

Salivary Gland Cancer Treatment Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest